Literature DB >> 29672723

An Analysis of The American Joint Committee on Cancer 8th Edition T Staging System for Papillary Thyroid Carcinoma.

Bryan Tran1,2, David Roshan1, Earl Abraham1, Laura Wang1, Natalia Garibotto1, James Wykes1,2, Peter Campbell1, Ardalan Ebrahimi1,2,3.   

Abstract

Background: The American Joint Committee on Cancer (AJCC) removed microscopic extrathyroidal extension (ETE) from the 8th edition T staging for papillary thyroid cancer (PTC) based on increasing evidence that it is not an independent prognostic factor.
Objectives: We compared the prognostic performance of AJCC 7th (pT7) and 8th (pT8) edition T stage systems, particularly in patients ≥55 years old without macroscopic ETE or distant metastases in whom T classification affects AJCC Tumor Node Metastasis (TNM) stage. Method: A retrospective analysis of disease-free survival (DFS) in 577 patients with PTC comparing pT8 vs pT7 using the Akaike information criterion (AIC), Harrell's C-index, and Proportion of Variation Explained (PVE).
Results: Of 105 patients with AJCC7 T3 disease, 74 were down-staged. Overall, the prognostic performance of pT7 and pT8 was similar. However, in patients ≥55 years old without macroscopic ETE or distant metastases, pT8 was inferior to pT7 on the basis of higher AIC, lower C-index (0.67 vs 0.76), and lower PVE (30% vs 45%). In this subset, microscopic ETE was associated with multiple other adverse prognostic features and reduced DFS (hazard ratio, 2.8; 95% confidence interval, 1.5 to 5.2; P = 0.002), irrespective of tumor size. Discussion: In our cohort, pT8 was inferior to pT7 in patients ≥55 years old without macroscopic ETE or distant metastases in whom T classification affects TNM stage. Microscopic ETE was strongly associated with other adverse prognostic factors and reduced DFS in this patient subgroup and may be an effective surrogate for disease biology in PTC, irrespective of whether it is an independent prognostic factor.

Entities:  

Mesh:

Year:  2018        PMID: 29672723     DOI: 10.1210/jc.2017-02551

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

1.  Contrast-enhanced ultrasound: a valuable modality for extracapsular extension assessment in papillary thyroid cancer.

Authors:  Yan Zhang; Xia Zhang; Jie Li; Qian Cai; Zhi Qiao; Yu Kun Luo
Journal:  Eur Radiol       Date:  2021-01-07       Impact factor: 5.315

2.  Assessment of the prognostic value and N1b changes of the eighth TNM/AJCC staging system for differentiated thyroid carcinoma.

Authors:  Jingtai Zhi; Yu Wu; Linfei Hu; Jingzhu Zhao; Hui Liu; Xianhui Ruan; Xiukun Hou; Jun Zhang; Xiangqian Zheng; Ming Gao
Journal:  Int J Clin Oncol       Date:  2019-08-14       Impact factor: 3.402

3.  Minimal extrathyroid extension in papillary micro carcinoma of the thyroid is an independent risk factor for relapse through lymph node and distant metastases.

Authors:  Robert Seifert; Michael Andreas Schäfers; Barbara Heitplatz; Laura Kerschke; Burkhard Riemann; Benjamin Noto
Journal:  J Nucl Med       Date:  2021-03-26       Impact factor: 11.082

4.  Prognostic Impact of Microscopic Extra-Thyroidal Extension (mETE) on Disease Free Survival in Patients with Papillary Thyroid Carcinoma (PTC).

Authors:  Nadia Bouzehouane; Pascal Roy; Myriam Decaussin-Petrucci; Mireille Bertholon-Grégoire; Chantal Bully; Agnès Perrin; Helene Lasolle; Jean-Christophe Lifante; Françoise Borson-Chazot; Claire Bournaud
Journal:  Cancers (Basel)       Date:  2022-05-24       Impact factor: 6.575

5.  Does macroscopic extrathyroidal extension to the strap muscles alone affect survival in papillary thyroid carcinoma?

Authors:  Victoria Harries; Marlena McGill; Avery Yuan; Laura Y Wang; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Richard J Wong; Snehal G Patel; Ian Ganly
Journal:  Surgery       Date:  2021-09-30       Impact factor: 4.348

6.  Evaluation of Clinicopathological and Molecular Parameters on Disease Recurrence of Papillary Thyroid Cancer Patient: A Retrospective Observational Study.

Authors:  Salvatore Sorrenti; Giovanni Carbotta; Filippo Maria Di Matteo; Antonio Catania; Daniele Pironi; Francesco Tartaglia; Danilo Tarroni; Federica Gagliardi; Domenico Tripodi; Mikiko Watanabe; Stefania Mariani; Eleonora D'Armiento; Poupak Fallahi; Alessandro Sindoni; Corrado De Vito; Alessandro Antonelli; Salvatore Ulisse; Enke Baldini
Journal:  Cancers (Basel)       Date:  2020-12-04       Impact factor: 6.639

7.  Does Microscopic Extrathyroidal Extension Confer a Higher Risk of Recurrence in Patients With Well-Differentiated Thyroid Cancer?

Authors:  Furio Pacini
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

8.  A Radiomic Nomogram for the Ultrasound-Based Evaluation of Extrathyroidal Extension in Papillary Thyroid Carcinoma.

Authors:  Xian Wang; Enock Adjei Agyekum; Yongzhen Ren; Jin Zhang; Qing Zhang; Hui Sun; Guoliang Zhang; Feiju Xu; Xiangshu Bo; Wenzhi Lv; Shudong Hu; Xiaoqin Qian
Journal:  Front Oncol       Date:  2021-03-04       Impact factor: 6.244

9.  Impacts of the American Joint Committee on Cancer (AJCC) 8th edition tumor, node, metastasis (TNM) staging system on outcomes of differentiated thyroid cancer in Thai patients.

Authors:  Yotsapon Thewjitcharoen; Waralee Chatchomchuan; Krittadhee Karndumri; Sriurai Porramatikul; Sirinate Krittiyawong; Ekgaluck Wanothayaroj; Siriwan Butadej; Soontaree Nakasatien; Veekij Veerasomboonsin; Auchai Kanchanapituk; Rajata Rajatanavin; Thep Himathongkam
Journal:  Heliyon       Date:  2021-03-30

10.  Upregulation of sphingosine kinase 1 is associated with recurrence and poor prognosis in papillary thyroid carcinoma.

Authors:  Jie Li; Bo Zhang; Yang Bai; Yonghong Liu; Buyong Zhang; Jian Jin
Journal:  Oncol Lett       Date:  2019-09-24       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.